BCL2 and B-cell chronic lymphocytic leukemia: For example, the regulation of BCL2 via TCF4 predicted in our GREN (Appendix Fig S7) is of special interest since it is the target of venetoclax, a highly effective treatment option in CLL (Roberts et al, 2016).